0000000000242586

AUTHOR

Ewa Czyz

showing 4 related works from this author

Assessment of microRNAs in patients with unstable angina pectoris.

2014

Aims While cardiac troponin measurements have significantly improved the early diagnosis of myocardial infarction, the timely biomarker-based diagnosis of unstable angina pectoris (UAP) remains a major unmet clinical challenge. The aim of this study was to assess levels of circulating microRNAs (miRNAs) as possible novel biomarkers in patients with UAP. Methods and results A three-phase approach was conducted, comprising (i) profiling of miRNAs in patients with UAP and controls groups; (ii) replication of significant miRNAs in an independent patient cohort, (iii) validation of a multi-miRNAs panel in a third cohort. Out of 25 miRNAs selected for replication, 8 miRNAs remained significantly …

OncologyAdultGenetic MarkersMalemedicine.medical_specialtyMyocardial InfarctionDiscriminatory powerInternal medicinemicroRNAmedicineHumansIn patientMyocardial infarctionAngina UnstableAgedUnstable anginabusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseCirculating MicroRNAMicroRNAsEarly DiagnosisGenetic TechniquesROC CurveCase-Control StudiesCohortCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct

Copeptin Improves Early Diagnosis of Acute Myocardial Infarction

2010

ObjectivesEarly identification of myocardial infarction in chest pain patients is crucial to identify patients at risk and to maintain a fast treatment initiation.BackgroundThe aim of the current investigation is to test whether determination of copeptin, an indirect marker for arginin-vasopressin, adds diagnostic information to cardiac troponin in early evaluation of patients with suspected myocardial infarction.MethodsBetween January 2007 and July 2008, patients with suspected acute coronary syndrome were consecutively enrolled in this multicenter study. Copeptin, troponin T (TnT), myoglobin, and creatine kinase-myocardial band were determined at admission and after 3 and 6 h.ResultsOf 1,…

AdultMalemedicine.medical_specialtyAcute coronary syndromechest paindiagnosisMyocardial InfarctionChest painAngina PectorisCopeptinTroponin TPredictive Value of TestsInternal medicinemedicineHumansMyocardial infarctionProspective StudiesAgedTroponin TtroponinUnstable anginabusiness.industryMyoglobinTroponin IGlycopeptidescopeptinMiddle Agedmedicine.diseaseEarly DiagnosisCardiologyMyocardial infarction complicationsFemaleMyocardial infarction diagnosismedicine.symptombusinessCardiology and Cardiovascular MedicineBiomarkersJournal of the American College of Cardiology
researchProduct

Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction

2009

BACKGROUND Cardiac troponin testing is central to the diagnosis of acute myocardial infarction. We evaluated a sensitive troponin I assay for the early diagnosis and risk stratification of myocardial infarction. METHODS In a multicenter study, we determined levels of troponin I as assessed by a sensitive assay, troponin T, and traditional myocardial necrosis markers in 1818 consecutive patients with suspected acute myocardial infarction, on admission and 3 hours and 6 hours after admission. RESULTS For samples obtained on admission, the diagnostic accuracy was highest with the sensitive troponin I assay (area under the receiver-operating-characteristic curve [AUC], 0.96), as compared with t…

MaleChest Painmedicine.medical_specialtyMyocardial InfarctionComorbiditySensitivity and SpecificityAnginaElectrocardiographyTroponin TPredictive Value of TestsInternal medicineTroponin ImedicineHumansAngina UnstableMyocardial infarctionAgedbiologymedicine.diagnostic_testbusiness.industryTroponin IHazard ratioGeneral MedicineMiddle Agedmedicine.diseaseTroponinEarly DiagnosisROC CurveArea Under CurvePredictive value of testsbiology.proteinCardiologyFemaleMyocardial infarction diagnosisbusinessElectrocardiographyBiomarkersNew England Journal of Medicine
researchProduct